Context Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Martin Lehr
Chief executive officer
US$860.7k
Total compensation
| CEO salary percentage | 57.1% |
| CEO tenure | 10yrs |
| CEO ownership | 1.3% |
| Management average tenure | 3.2yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Aug 15
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$30m |
| Jun 30 2024 | n/a | n/a | -US$19m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$861k | US$492k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$21m |
| Jun 30 2023 | n/a | n/a | -US$19m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$1m | US$477k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$2m | US$291k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$648k |
| Dec 31 2020 | US$250k | US$250k | US$1m |
| Dec 31 2019 | US$250k | US$250k | -US$6m |
Compensation vs Market: Martin's total compensation ($USD860.68K) is above average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.
CEO
Martin Lehr (40 yo)
10yrs
Tenure
US$860,681
Compensation
Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. Mr. Lehr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10yrs | US$860.68k | 1.31% $ 1.2m | |
| CFO & Treasurer | 3.2yrs | US$606.68k | 0.053% $ 50.0k | |
| Chief Legal Officer & Corporate Secretary | 3.8yrs | US$582.15k | 0.083% $ 77.5k | |
| Senior Vice President of Operations | 3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
3.2yrs
Average Tenure
45yo
Average Age
Experienced Management: CNTX's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10yrs | US$860.68k | 1.31% $ 1.2m | |
| Independent Chairman of the Board | 3.8yrs | US$105.17k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$76.33k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$79.83k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$59.83k | 0.0047% $ 4.4k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
3.8yrs
Average Tenure
59yo
Average Age
Experienced Board: CNTX's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 09:04 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Context Therapeutics Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Soo Romanoff | Edison Investment Research |
| Emily Bodnar | H.C. Wainwright & Co. |